Ozempic – Artifex.News https://artifex.news Stay Connected. Stay Informed. Sat, 15 Aug 2026 07:19:00 +0000 en-US hourly 1 https://wordpress.org/?v=7.1.3 https://artifex.news/wp-content/uploads/2026/05/cropped-cropped-app-logo-32x32.png Ozempic – Artifex.News https://artifex.news 32 32 Notices to 43 medical shops in Telangana over sale of Mounjaro, Ozempic without prescription https://artifex.news/article71348448-ecerand29/ Sat, 15 Aug 2026 07:19:00 +0000 https://artifex.news/article71348448-ecerand29/ Read More “Notices to 43 medical shops in Telangana over sale of Mounjaro, Ozempic without prescription” »

]]>

The Telangana Drugs Control Administration (DCA) has issued show-cause notices to 43 medical shops after detecting violations in the sale of weight-loss drugs during a special enforcement drive across the State on August 14, 2026
| Photo Credit: Special Arrangement

The Telangana Drugs Control Administration (DCA) has issued show-cause notices to 43 medical shops after detecting violations in the sale of weight-loss drugs, including Mounjaro, Ozempic, Wegovy and Rybelsus, during a special enforcement drive across the State on Friday (August 14, 2026).

The inspections were conducted amid growing demand for weight-loss formulations containing Tirzepatide and Semaglutide. The drive also focused on detecting spurious and counterfeit versions of these medicines and violations in their sale.

During the inspections, officials found several instances of non-compliance including sale of the drugs without a prescription from a specialist, failures to issue bills, not maintaining or producing sales bills and prescription drug registers, dispensing prescription medicines in the absence of a registered pharmacist and failing to produce purchase bills. Irregularities in maintaining copies of sales and purchase bills were also detected.

The drive covered medicines containing Tirzepatide, such as Mounjaro, and Semaglutide formulations including Ozempic, Wegovy and Rybelsus. It also covered generic equivalents of Semaglutide, including multi-dose vials and pre-filled pens manufactured by various companies and introduced into the market following the expiry of patents for innovator Semaglutide formulations.

The DCA said the show-cause notices had been issued to all 43 shops for violations and that further action would be taken under the Drugs and Cosmetics Act, 1940 and the rules framed under it.

Telangana DCA toll-free number

The Drugs Control Administration said suspected spurious or counterfeit weight-loss drugs, as well as instances of their illegal sale, promotion or misuse, can be reported through its toll-free number 18005996969, which operates from 10.30 a.m. to 5 p.m. on working days.

Published – August 15, 2026 12:48 pm IST



Source link

]]> Popular Weight Loss Drug Ozempic Could Increase Risk Of Blindness, Study Says https://artifex.news/popular-weight-loss-drug-ozempic-could-increase-risk-of-blindness-study-says-7299243/ Sat, 21 Dec 2024 05:40:27 +0000 https://artifex.news/popular-weight-loss-drug-ozempic-could-increase-risk-of-blindness-study-says-7299243/ Read More “Popular Weight Loss Drug Ozempic Could Increase Risk Of Blindness, Study Says” »

]]>

Recent studies have uncovered a frightening association between the popular diabetes and weight loss drugs, Ozempic and Wegovy, with a rare eye disorder that may cause blindness.

A study, published in the medical journal JAMA Ophthalmology, reported that individuals on those drugs containing semaglutide have a much larger percentage chance of acquiring NAION, or, more precisely known by its acronym, non-arteritic anterior ischaemic optic neuropathy.

This is defined by a lack of flow through the optic nerve, suddenly damaging one’s vision since that nerve has more than one million strands. NAION is a rare condition, affecting only 2 to 10 people per 100,000. It is the second leading cause of optic nerve blindness, and there is currently no effective cure.

The study revealed that those using semaglutide for diabetes were four times more likely to develop NAION than those not using the drug. Those using it for weight loss had even greater risk-more than seven times higher.

“To be perfectly clear, I would not take my findings and use them to recommend that patients stop taking their medications,” says Dr Rizzo. “Our finding was really the first possible significant negative finding with these drugs. It may just merit extra caution in the consideration between doctors and patients about who may use this medicine.”

According to the study, semaglutide is linked to a seven-fold increased risk of NAION when taken to treat obesity and a four-fold increased risk when used to treat type 2 diabetes.

Among the 710 patients with Type 2 diabetes, semaglutide users had an 8.9% chance of developing NAION, while those on other medicines had a 1.8% chance.

The rate of NAION development was 6.7% for patients administered semaglutide for weight loss and 0.8% for patients on other medicines.




Source link

]]>